A comparison of selective angiotensin II1 receptor antagonists

Current Therapeutics

Volumn 40, Issue 3, 1999, Pages 45-52

  Johnson, Tony ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033241283     PISSN: 0311905X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ferrario CM. Importance of the renin-angiotensin-aldosterone system (RAS) in the physiology and pathology of hypertension: an overview. Drugs 1990; 39 Suppl. 2: 1-8
2. Laragh JH, Baer L, Brunner HR, et al. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52: 633-52
3. Unger T, Culman J, Gohlke P. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens Suppl 1998; 16: S3-9
4. Menard J, Chatellier G, Azizi M. Do we need angiotensin II antagonists to treat hypertensive patients? J Hum Hypertens 1997; 11 Suppl. 2: S1-7
5. Pals DT, Masucci FD, Sipos F, et al. A specific competitive antagonist of the vascular action of angiotensin II. Circ Res 1971; 29: 664-72
6. Csajka C, Buclin T, Brunner HR, et al. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet 1997; 32: 1-29
7. Bauer JH, Reams PG. The angiotensin II type 1 receptor antagonists: a new class of antihypertensive drugs. Arch Intern Med 1995; 155: 1361-8
8. Lo M, Goldberg M, McCrea J, et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58: 641-9
9. Kazierad DJ, Martin DE, Blum RA, et al. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997; 62: 417-25
10. McCrea J, Lo MW, Kong T, et al. A rare deficiency of the conversion of losartan to its active metabolite E3174. Clin Phannacol Ther 1995; 57: 154
11. Spielberg S, McCrea J, Cribb A, et al. A mutation in CYP2C9 is responsible for decreased metabolism of losartan. Clin Pharmacol Ther 1996; 59: 215
12. van Lier JJ, van Heiningen PN, Sunzel M. Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997; 11 Suppl. 2: S27-28
13. Riddell G. Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil. J Hum Hypertens 1997; 11 Suppl. 2: S29-30
14. Ogihara T, Nagano M, Mikami H, et al. Effects of the angiotensin II antagonist, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects. Clin Ther 1994; 16: 74-86
15. Hubner R, Hogemann AM, Sunzel M, et al. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997; 11 Suppl. 2: S19-25
16. de Zeeuw D, Remuzzi G, Kirch W. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment. J Hum Hypertens 1997: 11 Suppl. 2: S37-42
17. Criscione L, Bradley WA, Buhlmayer P et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 1995; 13: 230-50
18. Markham A, Goa KL. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54: 299-311
19. Waldmeier F, Flesch G, Muller P, et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 1997; 27: 59-71
20. Sioufi A, Marfil F, Jaouen A, et al. The effect of age on the pharmacokinetics of valsartan [abstract]. Eur J Drug Metab Pharmacokinet 1996 (Special Issue): 86
21. Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54: 885-902
22. Delacretaz E, Nussberger J, Biollaz J, et al. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 25: 14-21
23. Kalbag J, Prasad P, Redalieu E, et al. Plasma concentrations and antihypertensive effect of 10 to 160 mg doses of valsartan (VAL) in hypertensive patients. Pharm Res 1994; 11 Suppl.: S367
24. Ohtawa M, Takayama F, Saitoh K, et al. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993; 35: 290-7
25. Olins G, Chen ST, McMahon EG, et al. Elucidation of the insurmountable nature of an angiotensin receptor antagonist, SC-54629. Mol Pharmacol 1995; 47: 115-20
26. Nishikawa K, Naka T, Chatani F, et al. Candesartan cilexetil: a review of its preclinical pharmacology. J Hum Hypertens 1997; 11 Suppl. 2: S9-17
27. Muller P, Cohen T, De Gasparo M, et al. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994; 47: 231-45
28. Nakashima M, Uematsu T, Kosuge K, et al. Pilot study of the uricosuric effect of DUP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42: 333-5
29. Burnier M, Pechere-Bertschi A, Nussberger J, et al. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems. Am J Kidney Dis 1995; 26: 108-15
30. Oddou-Stock P, Gatlin M, Kobi P, et al. Comparison of the efficacy of two angiotensin II antagonists, valsartan and losartan, in essential hypertension [abstract]. Am J Hypertens 1997; 10: 84A
31. Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 1998; 11: 445-53
32. Andersson OK, Neldham S. Comparison of candesartan cilexetil and losartan in mild-to-moderate hypertension. J Hum Hypertens 1997; 1 Suppl. 2: S63-4